Seeking Alpha

Ampio Pharmaceuticals updates Optina dose finding study

  • Ampio Pharmaceuticals (AMPE +3.4%) reports interim results from a dose finding trial of Optina in DME.
  • Ultimately, the IDRC recommended the continuation of the trial as "it was determined that there was a treatment dosage that was demonstrating a potentially beneficial anatomic effect [and] there were no significant safety concerns."
  • Once the trial is complete, the company will immediately initiate an open label extension study using the determined optimum dose. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector